John de Koning

John de Koning, PhD, joined LSP in 2006 and became partner in 2009. He serves or has served on the supervisory boards of arGEN-X (NL), BMEYE (NL), Innovative Biosensors Inc (USA), Merus (NL), Pronota (BEL), Prosensa (NL) and Skyline Diagnostics (NL). From 2001 to 2005, John was at Semaia Pharmaceuticals (NL), a portfolio company of LSP. In 2003, Semaia Pharmaceuticals was acquired by Hybrigenics (F), where John set up Target Discovery and became Managing Director of Semaia. In addition, he was a member of the management team responsible for technology transfer at a large oncology consortium of leading Dutch scientists funded by the Dutch government, called the Cancer Genomics Center, a center of excellence of the Netherlands Genomics Initiative. John has a Master’s degree in molecular biology from the University of Utrecht and a PhD in oncology from the Erasmus University of Rotterdam. After his PhD, John received a prestigious fellowship from the Dutch Cancer Society to work at the UCSF Cancer Center in San Francisco. His results were published in numerous leading scientific journals, including Nature Genetics. In addition to these achievements, John is inventor on several patents.